Inebilizumab vs UTAA09

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Systemic Lupus Erythematosus

Shared mechanism: CD19 · full Systemic Lupus Erythematosus pipeline

Inebilizumab

Marketed by Amgen and partners

Phase 2 in Systemic Lupus Erythematosusmonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: August 2028 · NCT06570798 (registry estimate)

No aligned efficacy figure on record for this race.

UTAA09

Developed by PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Phase 1 in Systemic Lupus ErythematosusCAR-T cell therapy
Weak signal

NCT06417398 · Phase 1 · status unknown

This is an open-label, single-arm study with no control group and only 10 patients, and it has not yet reported any results, so there is no controlled evidence here yet.

No aligned efficacy figure on record for this race.

Results for Systemic Lupus Erythematosus

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointInebilizumabUTAA09
SRI-4—Not reported—Not reported
BICLA—Not reported—Not reported
CLASI-50—Not reported—Not reported
Steroid sparing—Not reported—Not reported

SRI-4

Inebilizumab
—Not reported
UTAA09
—Not reported

BICLA

Inebilizumab
—Not reported
UTAA09
—Not reported

CLASI-50

Inebilizumab
—Not reported
UTAA09
—Not reported

Steroid sparing

Inebilizumab
—Not reported
UTAA09
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Inebilizumab: no structured comparison results are available for Systemic Lupus Erythematosus.

UTAA09: no structured comparison results are available for Systemic Lupus Erythematosus.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Inebilizumab's landscape · UTAA09's landscape